BPC-157 and KPV
Is BPC-157 plus KPV a good gut stack, and should you take them orally or inject them?
Reviewed by the amino101 editorial team. .
Also searched as BPC KPV gut stack, BPC-157 KPV oral stack, gut healing peptide stack.
BPC-157 is a 15 amino acid fragment of a protective protein found in human gastric juice. People use it for tendon, ligament, muscle and gut healing, and it is one of the most widely used research peptides in the recovery space.
KPV is a three amino acid fragment of alpha-melanocyte stimulating hormone that carries the anti-inflammatory effect of the hormone without its pigmentation effect. It is used for inflammatory bowel symptoms, skin inflammation and general inflammation control.
BPC-157 and KPV are paired for the gut because they do different jobs there. BPC-157 is a fragment of a protective protein from gastric juice, it is stable in stomach acid, and it has the deepest rodent literature of any peptide on this site for protecting and repairing the gut lining. KPV is a three amino acid fragment of alpha-MSH that blocks NF-kB signaling and is carried into inflamed intestinal cells by the PepT1 transporter. One repairs tissue, the other turns down the inflammation that damages it. The evidence is animal work: rat ulcer and colitis studies for BPC-157, mouse colitis models for KPV. BPC-157 has a few small early phase human trials in inflammatory bowel disease that were reported as favorable but never published as full controlled trials. KPV has no human trials at all.
What makes this stack different from most others on the site is that both peptides can be taken orally, and for a gut target that may be the better route. This page covers oral versus injectable dosage for each, how long people run them, and when the pair is the wrong tool. The BPC-157 vs KPV page compares them head to head. Both are unapproved, and this is educational background rather than a treatment for any diagnosed condition.
Why people combine BPC-157 and KPV
BPC-157 increases VEGF signaling and cell migration into damaged tissue and interacts with the nitric oxide system to protect the mucosal barrier. KPV blocks NF-kB from entering the nucleus, which cuts TNF-alpha, IL-6 and IL-1 beta production. In a gut that is both inflamed and damaged, those are the two things you would want addressed, and neither peptide does the other's job.
BPC-157 survives gastric acid, which is unusual for a peptide and is why it was studied orally from the start. KPV is actively transported into intestinal epithelial cells, and that transporter is upregulated during inflammation. For a gut target, oral dosing puts both peptides in contact with the tissue rather than relying on blood levels.
This is one of the few stacks where capsules are a reasonable default. People with needle aversion, or who want to try peptides for a gut complaint before committing to injections, start here. Oral BPC-157 at 250 to 500 mcg and oral KPV at 500 mcg to 1 mg are both low cost, and the oral vs injectable BPC-157 article covers what is known about absorption.
Neither peptide diagnoses anything. Blood in the stool, unexplained weight loss, persistent pain or a family history of bowel cancer need a colonoscopy, not a peptide protocol that suppresses the inflammation a doctor would use to find the problem. The stack also adds nothing for a tendon or a joint; that is BPC-157 alone, injected.
BPC-157 and KPV dosage and protocol
What appears in research and community protocols for each compound in the stack. Not a prescription.
| Peptide | Dosage | Frequency | Timing and route |
|---|---|---|---|
| BPC-157 | 250 to 500 mcg | once or twice daily | oral capsule on an empty stomach for gut complaints, or subcutaneous in the abdomen |
| KPV | 500 mcg to 1 mg oral; 250 to 500 mcg injectable or nasal | once or twice daily | oral capsule on an empty stomach, 30 minutes or more before food, or subcutaneous in the abdomen |
4 to 8 weeks is the usual run for both, then a stop to see whether symptoms return, which is the only way to tell whether the peptides were responsible. For chronic conditions some people use the pair only around flares rather than continuously. A 2 to 4 week break is standard before any repeat, and there is no long term safety data for either compound.
- •Oral doses go on an empty stomach so the peptides contact the lining directly and KPV is not competing with dietary protein for the PepT1 transporter. Many people take both capsules together first thing in the morning.
- •Oral KPV quality varies. The mouse colitis work used protective nanoparticle formulations that most vendors do not sell, so plain capsules may lose some peptide to digestion.
- •Injectable is the fallback if oral does nothing after 2 to 3 weeks, or if the problem is systemic rather than confined to the gut.
- •Most people pause KPV during an active infection, including a gut infection.
Work out syringe units for any of these in the dosage calculator.
Can you mix BPC-157 and KPV in one syringe?
For the oral route there is nothing to mix; the capsules are taken together. For the injectable route both are reconstituted with bacteriostatic water and have no known conflict, so people draw them into one syringe, though no stability data exists for the mixture and there is no copper or pH issue to worry about. Some vendors sell a BPC-157 and KPV blend, usually 5 mg of each in one vial, and because the doses are similar the fixed ratio works. The reconstitution guide covers the volumes for the injectable version.
What to expect, week by week
- Week 1 to 2
Less bloating, urgency or discomfort is the most common early report from both compounds. Nausea from the capsules can show up in the first days and usually fades.
- Week 3 to 4
If KPV is going to help, the effect is usually clear by now as a steady reduction in background inflammation rather than a dramatic change. BPC-157's gut effects are typically judged at 1 to 3 weeks.
- Week 5 to 8
Gains plateau. This is when most people stop and watch for symptoms coming back, which is the only real test of whether the stack was doing anything.
- After stopping
Symptoms that return within 2 to 4 weeks are the signal people use to decide on another run or a flare-only pattern.
Side effects and cautions
- ▲Nausea, more often with oral BPC-157 capsules and with injectable KPV
- ▲Stomach upset from oral KPV capsules in some people
- ▲Headache, reported with both
- ▲Injection site redness or irritation if the injectable route is used
- ▲Fatigue, reported by a minority of KPV users
- ▲Rare reports of mood changes with BPC-157
- ■Undiagnosed gut symptoms, especially blood in the stool, weight loss, fever or pain that wakes you. A diagnosis comes first.
- ■Anyone on immunosuppressants, TNF blockers or other biologics for inflammatory bowel disease. Adding KPV has never been studied and the prescriber needs to know.
- ■An active infection, including gut infections. KPV suppresses NF-kB broadly and is usually paused; BPC-157 does not treat an infection either.
- ■Active or recent cancer, because of BPC-157's angiogenesis effect, and tested athletes, because BPC-157 is WADA prohibited.
BPC-157 and KPV is the gut stack for someone with a diagnosed or at least evaluated inflammatory gut problem who wants to try peptides without needles. It is cheap, oral, and the two compounds do different jobs. The evidence is rodent studies and a handful of unpublished human pilots, so expectations need to stay modest, and the only way to know it worked is to stop and watch. Someone whose main symptom is upper gut pain, NSAID irritation or a healing ulcer can reasonably start with BPC-157 alone, which has the deeper literature. Someone with a flare of inflammatory symptoms and no tissue damage to speak of can try KPV alone. Running both from day one means never learning which one helped. Anyone with alarm symptoms needs a colonoscopy first, anyone on a biologic needs their prescriber's input, and nobody should treat this page as more than educational background.
BPC-157 and KPV: frequently asked
Should you take BPC-157 and KPV orally or inject them?
For gut complaints, oral is the usual starting point for both because the target is the lining they pass through. Injectable is used when oral does nothing, when the problem is systemic, or when the goal includes tendon or muscle repair. There is no human study comparing the routes for either peptide; see oral vs injectable BPC-157.
What is the BPC-157 and KPV dosage?
Reported oral protocols use BPC-157 at 250 to 500 mcg and KPV at 500 mcg to 1 mg, each once or twice daily on an empty stomach. Injectable protocols use 250 to 500 mcg of each. The peptide dosage chart lists both.
Can you take BPC-157 and KPV at the same time?
Yes. Both capsules are usually taken together first thing in the morning, 30 minutes or more before food. If injecting, both can go in one syringe.
Is BPC-157 or KPV better for IBS or IBD symptoms?
They address different things. KPV is the one with anti-inflammatory mouse colitis data; BPC-157 is the one with ulcer, fistula and mucosal barrier data plus small human IBD pilots. For symptoms driven by inflammation, KPV; for damage and healing, BPC-157; which is why people run both. See BPC-157 vs KPV.
How long does the BPC-157 and KPV gut stack take to work?
Gut symptom changes are usually reported within 1 to 3 weeks. If nothing has shifted by week 4, the oral route or the stack itself probably is not the answer. Most runs end at 4 to 8 weeks.
Is KPV the same as melanotan?
No. Both derive from alpha-MSH, but KPV is the fragment that does not bind the pigment receptor. It does not cause tanning and has no overlap in effect with melanotan.
Related reading
Healing with inflammation and gut support
Soft tissue and tendon injury recovery
Both are gut peptides. One repairs, one calms inflammation. Which problem do you have?
Which healing peptide should you start with, and do you need both?
Guide
Dosage
Guide
Skin, scar and post-procedure healing
Sources
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008